You'd think its lead drug failed a clinical trial or the Food and Drug Administration turned down the drug...Instead, the FDA simply didn't agree with Exelixis in how to take a shortcut to approval. The agency has a process called a Special Protocol Assessment, or SPA, where companies can get the FDA...
FULL ARTICLE AT The Motley Fool